166 related articles for article (PubMed ID: 23072245)
61. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
[TBL] [Abstract][Full Text] [Related]
62. Letter: should immunosuppressive therapy be started with adalimumab in Crohn's disease? Authors' reply.
Reenaers C; Louis E; Belaiche J; Seidel L; Keshav S; Travis S
Aliment Pharmacol Ther; 2013 Apr; 37(7):752-3. PubMed ID: 23458531
[No Abstract] [Full Text] [Related]
63. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
Gupta A; Pendyala P; Arora P; Sitrin MD
J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
[TBL] [Abstract][Full Text] [Related]
64. Adalimumab-induced lichenoid drug eruption.
El Habr C; Meguerian Z; Sammour R
J Med Liban; 2014; 62(4):238-40. PubMed ID: 25807724
[TBL] [Abstract][Full Text] [Related]
65. New pancreatic adenocarcinoma in a Crohn's patient treated with tumor necrosis factor (TNF) inhibitors for 6 months.
Patel R; Lara S; Johnson J; Kulkarni P
J Gastrointest Cancer; 2014 Dec; 45 Suppl 1():226-9. PubMed ID: 25027498
[No Abstract] [Full Text] [Related]
66. Reactivation of latent tuberculosis in a Crohn's patient after TB prophylaxis treated with adalimumab.
Caldera F; Grimes I; Soni A
Am J Gastroenterol; 2013 Jul; 108(7):1181-2. PubMed ID: 23821003
[No Abstract] [Full Text] [Related]
67. Probable diffuse retinopathy caused by adalimumab in a patient with Crohn's disease.
Marticorena-Álvarez P; Chaparro M; Pérez-Casas A; Muriel-Herrero A; Gisbert JP
J Crohns Colitis; 2012 Oct; 6(9):950-3. PubMed ID: 22537636
[TBL] [Abstract][Full Text] [Related]
68. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
[TBL] [Abstract][Full Text] [Related]
69. Monoclonals against TNF are a major advance in the treatment of Crohn's disease.
Fraser A
N Z Med J; 2014 Jun; 127(1396):10-4. PubMed ID: 24997459
[No Abstract] [Full Text] [Related]
70. Adalimumab for perianal fistulizing Crohn's disease: real-world data adds important information for clinical practice.
Kotze PG; Spinelli A
J Clin Gastroenterol; 2015 Feb; 49(2):174-5. PubMed ID: 25159683
[No Abstract] [Full Text] [Related]
71. Adalimumab for the treatment of inflammatory bowel disease.
Wasan SK; Kane SV
Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
[TBL] [Abstract][Full Text] [Related]
72. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
73. What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?
Kabaçam G; Törüner M
Turk J Gastroenterol; 2010 Mar; 21(1):107-12. PubMed ID: 20552736
[No Abstract] [Full Text] [Related]
74. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
Lie MR; Peppelenbosch MP; West RL; Zelinkova Z; van der Woude CJ
Aliment Pharmacol Ther; 2014 Nov; 40(10):1202-8. PubMed ID: 25263077
[TBL] [Abstract][Full Text] [Related]
75. Anti-TNF antibody therapy in Crohn's disease: the risk of a switch.
Ricart E; Ordás I; Panés J
Gut; 2012 Feb; 61(2):169-70. PubMed ID: 22068167
[No Abstract] [Full Text] [Related]
76. The classics in perspective.
Panés J; Ghosh S
Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
[No Abstract] [Full Text] [Related]
77. Editorial: drug monitoring targets for optimising adalimumab in Crohn's disease.
Swoger JM; Levesque BG
Aliment Pharmacol Ther; 2014 Oct; 40(7):854-5. PubMed ID: 25185733
[No Abstract] [Full Text] [Related]
78. Certolizumab (Cimzia) for Crohn's disease.
Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
[No Abstract] [Full Text] [Related]
79. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
Eshuis EJ; Griffioen GH; Stokkers PC; Ubbink DT; Bemelman WA
Colorectal Dis; 2012 May; 14(5):578-84. PubMed ID: 21848898
[TBL] [Abstract][Full Text] [Related]
80. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
